{
    "Trade/Device Name(s)": [
        "Finetest Lite Blood Glucose Monitoring System"
    ],
    "Submitter Information": "OSANG Healthcare Co., Ltd.",
    "510(k) Number": "K203562",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132966"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "July 13, 2021",
    "Summary Letter Received Date": "December 7, 2020",
    "Submission Date": "November 12, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Finetest Lite Blood Glucose meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test strip",
        "Control solution",
        "Lancing device"
    ],
    "Document Summary": "FDA 510(k) summary for Finetest Lite Blood Glucose Monitoring System for quantitative measurement of glucose in fresh capillary whole blood",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from various body sites by single patients at home as an aid to monitor diabetes control; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}